These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19538213)

  • 1. Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany.
    Madzar D; Schulte C; Gasser T
    Eur J Neurol; 2009 Nov; 16(11):1230-2. PubMed ID: 19538213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lrrk2 R1441 substitution and progressive supranuclear palsy.
    Ross OA; Whittle AJ; Cobb SA; Hulihan MM; Lincoln SJ; Toft M; Farrer MJ; Dickson DW
    Neuropathol Appl Neurobiol; 2006 Feb; 32(1):23-5. PubMed ID: 16409550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
    Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
    Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP.
    Spanaki C; Latsoudis H; Plaitakis A
    Neurology; 2006 Oct; 67(8):1518-9. PubMed ID: 17060595
    [No Abstract]   [Full Text] [Related]  

  • 5. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.
    Sanchez-Contreras M; Heckman MG; Tacik P; Diehl N; Brown PH; Soto-Ortolaza AI; Christopher EA; Walton RL; Ross OA; Golbe LI; Graff-Radford N; Wszolek ZK; Dickson DW; Rademakers R
    Mov Disord; 2017 Jan; 32(1):115-123. PubMed ID: 27709685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
    Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
    J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of three novel LRRK2 mutations associated with Parkinson's disease in a Calabrian population.
    Anfossi M; Colao R; Gallo M; Bernardi L; Conidi ME; Frangipane F; Vasso F; Puccio G; Clodomiro A; Mirabelli M; Curcio SA; Torchia G; Smirne N; Di Lorenzo R; Maletta R; Bruni AC
    J Alzheimers Dis; 2014; 38(2):351-7. PubMed ID: 23963289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
    Lesage S; Janin S; Lohmann E; Leutenegger AL; Leclere L; Viallet F; Pollak P; Durif F; Thobois S; Layet V; Vidailhet M; Agid Y; Dürr A; Brice A; ; Bonnet AM; Borg M; Broussolle E; Damier P; Destée A; Martinez M; Penet C; Rasco O; Tison F; Tranchan C; Vérin M
    Arch Neurol; 2007 Mar; 64(3):425-30. PubMed ID: 17353388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
    Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
    Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel LRRK2 mutations in Parkinsonism.
    Trinh J; Guella I; McKenzie M; Gustavsson EK; Szu-Tu C; Petersen MS; Rajput A; Rajput AH; McKeown M; Jeon BS; Aasly JO; Bardien S; Farrer MJ
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1119-21. PubMed ID: 26213354
    [No Abstract]   [Full Text] [Related]  

  • 12. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant.
    Pchelina SN; Yakimovskii AF; Emelyanov AK; Ivanova ON; Schwarzman AL; Singleton AB
    Eur J Neurol; 2008 Jul; 15(7):692-6. PubMed ID: 18435766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study.
    Jabbari E; Koga S; Valentino RR; Reynolds RH; Ferrari R; Tan MMX; Rowe JB; Dalgard CL; Scholz SW; Dickson DW; Warner TT; Revesz T; Höglinger GU; Ross OA; Ryten M; Hardy J; Shoai M; Morris HR;
    Lancet Neurol; 2021 Feb; 20(2):107-116. PubMed ID: 33341150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
    Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
    Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial aggregation of parkinsonism in progressive supranuclear palsy.
    Donker Kaat L; Boon AJ; Azmani A; Kamphorst W; Breteler MM; Anar B; Heutink P; van Swieten JC
    Neurology; 2009 Jul; 73(2):98-105. PubMed ID: 19458322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic screening for the LRRK2, G2019S and R1441 codon mutations in Parkinson's disease patients from Extremadura, Spain].
    Morán JM; Castellanos-Pinedo F; Casado-Naranjo I; Durán-Herrera C; Ramírez-Moreno JM; Gómez M; Zurdo-Hernández JM; Fuentes E; Ortiz-Ortiz MA; Moreno AD; González-Polo RA; Niso-Santano M; Bravo-Sanpedro JM; Pérez-Tur J; Ruiz-Mesa LM; Fuentes JM
    Rev Neurol; 2010 May; 50(10):591-4. PubMed ID: 20473834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease.
    Perez-Pastene C; Cobb SA; Díaz-Grez F; Hulihan MM; Miranda M; Venegas P; Godoy OT; Kachergus JM; Ross OA; Layson L; Farrer MJ; Segura-Aguilar J
    Neurosci Lett; 2007 Jul; 422(3):193-7. PubMed ID: 17614198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical molecular genetics for PARK8 (LRRK2)].
    Tomiyama H; Hatano T; Hattori N
    Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.